S&P 500   3,373.15 (-0.38%)
DOW   29,219.20 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
MSFT   184.51 (-1.48%)
GOOGL   1,517.04 (-0.51%)
AMZN   2,151.83 (-0.85%)
CGC   22.29 (+2.39%)
NVDA   309.08 (-1.79%)
BABA   218.09 (-1.82%)
GE   12.53 (-0.63%)
TSLA   898.88 (-2.02%)
AMD   57.31 (-2.70%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
DIS   140.44 (-0.61%)
S&P 500   3,373.15 (-0.38%)
DOW   29,219.20 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
MSFT   184.51 (-1.48%)
GOOGL   1,517.04 (-0.51%)
AMZN   2,151.83 (-0.85%)
CGC   22.29 (+2.39%)
NVDA   309.08 (-1.79%)
BABA   218.09 (-1.82%)
GE   12.53 (-0.63%)
TSLA   898.88 (-2.02%)
AMD   57.31 (-2.70%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
DIS   140.44 (-0.61%)
S&P 500   3,373.15 (-0.38%)
DOW   29,219.20 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
MSFT   184.51 (-1.48%)
GOOGL   1,517.04 (-0.51%)
AMZN   2,151.83 (-0.85%)
CGC   22.29 (+2.39%)
NVDA   309.08 (-1.79%)
BABA   218.09 (-1.82%)
GE   12.53 (-0.63%)
TSLA   898.88 (-2.02%)
AMD   57.31 (-2.70%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
DIS   140.44 (-0.61%)
S&P 500   3,373.15 (-0.38%)
DOW   29,219.20 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
MSFT   184.51 (-1.48%)
GOOGL   1,517.04 (-0.51%)
AMZN   2,151.83 (-0.85%)
CGC   22.29 (+2.39%)
NVDA   309.08 (-1.79%)
BABA   218.09 (-1.82%)
GE   12.53 (-0.63%)
TSLA   898.88 (-2.02%)
AMD   57.31 (-2.70%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
DIS   140.44 (-0.61%)
Log in

NASDAQ:PETS - Petmed Express Stock Price, Forecast & News

$28.35
+0.21 (+0.75 %)
(As of 02/20/2020 04:00 PM ET)
Today's Range
$27.46
Now: $28.35
$28.42
50-Day Range
$23.29
MA: $25.78
$28.68
52-Week Range
$15.00
Now: $28.35
$28.98
Volume259,511 shs
Average Volume446,312 shs
Market Capitalization$571.82 million
P/E Ratio22.68
Dividend Yield3.81%
Beta0.67
PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. It markets prescription and non-prescription pet medications, and other health products for dogs and cats directly to the consumers. The company offers non-prescription medications and supplies, including flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventative, flea and tick preventative, arthritis, thyroid, diabetes, pain, heart/blood pressure, and other specialty medications, as well as generic substitutes. Read More…

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryInternet Retail
SectorRetail/Wholesale
Current SymbolNASDAQ:PETS
CUSIP71638210
Phone561-526-4444

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$283.42 million
Cash Flow$1.93 per share
Book Value$6.33 per share

Profitability

Net Income$37.74 million

Miscellaneous

Employees187
Market Cap$571.82 million
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable

Receive PETS News and Ratings via Email

Sign-up to receive the latest news and ratings for PETS and its competitors with MarketBeat's FREE daily newsletter.


Petmed Express (NASDAQ:PETS) Frequently Asked Questions

What is Petmed Express' stock symbol?

Petmed Express trades on the NASDAQ under the ticker symbol "PETS."

How often does Petmed Express pay dividends? What is the dividend yield for Petmed Express?

Petmed Express announced a quarterly dividend on Tuesday, January 21st. Stockholders of record on Monday, February 3rd will be paid a dividend of $0.27 per share on Friday, February 14th. This represents a $1.08 annualized dividend and a dividend yield of 3.80%. The ex-dividend date is Friday, January 31st. View Petmed Express' Dividend History.

How were Petmed Express' earnings last quarter?

Petmed Express Inc (NASDAQ:PETS) issued its quarterly earnings results on Tuesday, January, 21st. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.30 by $0.04. The company earned $59.92 million during the quarter, compared to the consensus estimate of $61.31 million. Petmed Express had a return on equity of 19.91% and a net margin of 9.28%. Petmed Express's quarterly revenue was down .2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.38 earnings per share. View Petmed Express' Earnings History.

When is Petmed Express' next earnings date?

Petmed Express is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Petmed Express.

What price target have analysts set for PETS?

2 analysts have issued 1 year target prices for Petmed Express' shares. Their forecasts range from $20.00 to $29.00. On average, they anticipate Petmed Express' stock price to reach $24.50 in the next year. This suggests that the stock has a possible downside of 13.7%. View Analyst Price Targets for Petmed Express.

What is the consensus analysts' recommendation for Petmed Express?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Petmed Express in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Petmed Express.

Has Petmed Express been receiving favorable news coverage?

News stories about PETS stock have been trending extremely negative this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Petmed Express earned a media sentiment score of -4.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Petmed Express.

Are investors shorting Petmed Express?

Petmed Express saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 6,200,000 shares, a decline of 10.0% from the January 15th total of 6,890,000 shares. Based on an average daily volume of 585,600 shares, the short-interest ratio is currently 10.6 days. Currently, 32.1% of the shares of the stock are sold short. View Petmed Express' Current Options Chain.

Who are some of Petmed Express' key competitors?

What other stocks do shareholders of Petmed Express own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Petmed Express investors own include Intel (INTC), AT&T (T), Alibaba Group (BABA), NVIDIA (NVDA), Micron Technology (MU), Netflix (NFLX), Gilead Sciences (GILD), Ford Motor (F), Advanced Micro Devices (AMD) and Cisco Systems (CSCO).

Who are Petmed Express' key executives?

Petmed Express' management team includes the folowing people:
  • Mr. Menderes Akdag, CEO, Pres & Director (Age 58)
  • Mr. Bruce S. Rosenbloom, CFO & Treasurer (Age 50)
  • Ms. Alison Berges, Corp. Sec. & Gen. Counsel

Who are Petmed Express' major shareholders?

Petmed Express' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (8.02%), State Street Corp (3.80%), Man Group plc (3.25%), Bank of New York Mellon Corp (1.97%), Personal Capital Advisors Corp (1.54%) and Geode Capital Management LLC (1.47%). Company insiders that own Petmed Express stock include Bruce S Rosenbloom, Frank J Formica, Gian Fulgoni and Robert C Schweitzer. View Institutional Ownership Trends for Petmed Express.

Which major investors are selling Petmed Express stock?

PETS stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Newtyn Management LLC, UBS Group AG, Penserra Capital Management LLC, State Street Corp, Inlet Private Wealth LLC, Bank of New York Mellon Corp and Cubist Systematic Strategies LLC. Company insiders that have sold Petmed Express company stock in the last year include Bruce S Rosenbloom and Gian Fulgoni. View Insider Buying and Selling for Petmed Express.

Which major investors are buying Petmed Express stock?

PETS stock was acquired by a variety of institutional investors in the last quarter, including Citigroup Inc., FMR LLC, Goldman Sachs Group Inc., Man Group plc, Personal Capital Advisors Corp, Oxford Asset Management LLP, Chicago Equity Partners LLC and Cairn Investment Group Inc.. View Insider Buying and Selling for Petmed Express.

How do I buy shares of Petmed Express?

Shares of PETS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Petmed Express' stock price today?

One share of PETS stock can currently be purchased for approximately $28.40.

How big of a company is Petmed Express?

Petmed Express has a market capitalization of $572.83 million and generates $283.42 million in revenue each year. Petmed Express employs 187 workers across the globe.View Additional Information About Petmed Express.

What is Petmed Express' official website?

The official website for Petmed Express is http://www.1800petmeds.com/.

How can I contact Petmed Express?

Petmed Express' mailing address is 420 SOUTH CONGRESS AVENUE, DELRAY BEACH FL, 33445. The company can be reached via phone at 561-526-4444.


MarketBeat Community Rating for Petmed Express (NASDAQ PETS)

Community Ranking:  1.5 out of 5 (star half star)
Outperform Votes:  188 (Vote Outperform)
Underperform Votes:  440 (Vote Underperform)
Total Votes:  628
MarketBeat's community ratings are surveys of what our community members think about Petmed Express and other stocks. Vote "Outperform" if you believe PETS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PETS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel